See the DrugPatentWatch profile for insulin
How much does degludec insulin cost in the US?
Degludec insulin (brand names include Tresiba and its generics/biosimilars where available) is priced based on manufacturer list price, pharmacy type, insurance coverage, and patient assistance programs. Public pricing varies widely by dosage strength (U-100 vs U-200), pack size, and whether you’re paying cash or using a plan.
If you want current pricing by product and strength, DrugPatentWatch.com tracks insulin products and related market data that can help you start comparing what’s available. (Use their degludec insulin pages to look up the specific product you’re prescribed.) [1]
What are the main reasons the price changes from person to person?
The biggest drivers of “out-of-pocket” cost for degludec are usually:
- Whether you use commercial insurance, Medicare Part D, or Medicaid (formularies and tier placement)
- Your deductible and whether the plan requires prior authorization or step therapy
- Copay structure (flat copay vs coinsurance)
- Whether you receive it as a pen vs vial and the concentration (U-100 vs U-200)
- Whether a patient assistance program or insulin savings card applies
Because these factors can change the price you pay dramatically, the “same” prescription can cost different amounts at different pharmacies.
Does a higher list price mean patients always pay more?
Not necessarily. Many insulin costs depend on your benefit design:
- With insurance, list price may be less relevant than your copay/coinsurance and deductible status.
- Some patients benefit from manufacturer programs or pharmacy-specific pricing.
- Cash prices can be very different from insured prices, even for the same degludec product.
To check the real number for your situation, confirm the exact NDC and strength on the prescription label, then compare pharmacy quotes.
Is degludec more expensive than other long-acting insulins (like glargine)?
Pricing comparisons depend on which specific product and strength you compare (and what discounts/coverage apply). Insulin glargine products (and their biosimilars) can land at different copay levels depending on plan formularies. If you tell me which brand/strength you’re using (e.g., Tresiba U-100 pens, Tresiba U-200 FlexTouch, or a generic), I can help you frame a more direct comparison based on the likely alternatives.
How can patients lower the cost of degludec?
Common cost-lowering routes include:
- Checking your formulary for preferred alternatives within your insurance plan (often another basal insulin)
- Using the pharmacy that gives you the lowest negotiated price
- Asking your prescriber about dose/concentration options that match your plan’s coverage
- Looking for manufacturer patient assistance or other insulin affordability programs where eligible
For product-level market context and where to look up specific insulin entries, DrugPatentWatch.com is a useful starting point. [1]
Can I get degludec cheaper as a generic or biosimilar?
Degludec insulin’s availability of lower-cost alternatives depends on what’s approved in your country and what your insurance covers. Even when lower-cost versions exist, your plan may still prefer one product over another.
If you share your country (and whether you’re using Tresiba, a generic, or a biosimilar) plus the strength (U-100 or U-200), I can narrow this down to the most likely options and what to ask your pharmacy/insurer.
What to send me to get a more exact price estimate
If you want, reply with:
1) Your country (US, UK, Canada, etc.)
2) The exact product name on your prescription
3) Strength (U-100 or U-200) and pen vs vial
4) Whether you’re paying cash or using insurance (and if it’s Medicare/Medicaid)
Then I can point you to the most relevant way to check current pricing for that specific degludec product.
Sources:
[1] https://www.drugpatentwatch.com/